Skip to main navigation Skip to search Skip to main content

IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis

Marijn Vis, Wouter H Bos, Gertjan Wolbink, Alexandre E Voskuyl, Jos W R Twisk, Rob Van de Stadt, Dörte Hamann, Ben A C Dijkmans, Willem F Lems

Research output: Contribution to journal › Article › Academic › peer-review

Fingerprint

Dive into the research topics of 'IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology